Dr. Katie Murray discusses the diagnosis and management of non–muscle invasive bladder cancer, emphasizing cystoscopy and initial TURBT as the...

Indeterminate renal masses (IRMs) are a common diagnostic challenge, often leading to invasive biopsies, unnecessary surgery, or prolonged surveillance due...

The combination of belzutifan (WELIREG) plus lenvatinib (LENVIMA) met the primary endpoint of progression-free survival in the Phase 3 LITESPARK-011...

The FDA has granted full approval to rucaparib, an oral PARP inhibitor, for adults with BRCA1/2-mutated metastatic castration-resistant prostate cancer...

High-risk biochemically recurrent (hrBCR) prostate cancer represents a clinically challenging disease state, characterized by rising prostate-specific antigen (PSA) levels despite...

FDA approves Akeega (niraparib + abiraterone acetate with prednisone) for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant improvements in radiographic...

In the phase 3 PATINA trial, adding the CDK4/6 inhibitor palbociclib to maintenance HER2-targeted and endocrine therapy significantly prolonged progression-free...

The FDA has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer....

At SABCS 2025, new data evaluated whether multimodal artificial intelligence (MMAI) can be trusted to support clinical decision-making in early-stage...

Key data from SABCS 2025 highlight how endocrine-based, biology-driven strategies continue to reshape the management of ER-positive, HER2-negative breast cancer....

This article reviews recent pivotal HER2+ breast cancer trials, highlighting oral TKIs, antibody-drug conjugates, and chemotherapy-sparing strategies. Key studies—including HER2CLIMB-05,...

TUKYSA combo improves PFS in first-line HER2+ metastatic breast cancer maintenance, the first update to treatment paradigm since 2012.

Final results from the phase III FLAURA2 trial demonstrate that adding platinum–pemetrexed chemotherapy to first-line osimertinib significantly improves overall survival...

The FDA has approved subcutaneous amivantamab (Rybrevant Faspro) for adult patients with advanced or metastatic EGFR-mutated NSCLC. In the Phase...

The FDA has granted full approval to Tarlatamab-dlle (Imdelltra) for patients with extensive-stage small-cell lung cancer progressing after platinum therapy....

AI can extract critical genetic insights directly from routine pathology slides, streamlining decisions and accelerating targeted therapy access.

FDA approves lurbinectedin plus atezolizumab for ES-SCLC maintenance, extending OS to 13.2 months vs 10.6 months with atezolizumab alone (HR...

Five-year OS probability was 29.0% for cemiplimab and 15.0% for chemotherapy in advanced NSCLC patients with ≥50% PD-L1 expression.

HERIZON-GEA-01 is a pivotal phase III trial evaluating zanidatamab-based regimens, with or without the PD-1 inhibitor tislelizumab, compared with trastuzumab...

The phase III COMMIT trial demonstrates that intensifying first-line immunotherapy with chemotherapy and antiangiogenic therapy can substantially improve outcomes for...

Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) represent a biologically distinct subgroup with historically poor outcomes and limited first-line,...

The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with FLOT chemotherapy as the first and only perioperative immunotherapy for...

Patients with refractory metastatic colorectal cancer (mCRC) and microsatellite-stable (MSS) disease have limited treatment options and historically derive minimal benefit...

Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration...

ASCENT-03 trial shows Trodelvy plus pembrolizumab significantly improved PFS vs chemo plus pembrolizumab in first-line mTNBC patients.

FDA approves lurbinectedin plus atezolizumab for ES-SCLC maintenance, extending OS to 13.2 months vs 10.6 months with atezolizumab alone (HR...

FDA grants Priority Review for Enhertu plus pertuzumab in first-line HER2+ metastatic breast cancer, with decision expected April 2025.

FDA approves gemcitabine intravesical system for BCG-unresponsive bladder cancer, showing 82% complete response rate in SunRISe-1 trial.

Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the US.

Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk patients.